clear-cut win cohort
reduc estim profit warn retain confid chicken
updat fx sale
public contain summari recent credit suiss research report bring notabl research attent full report summari
certif legal entiti disclosur inform statu non-u analyst equiti research disclosur click
strategi econom strategi
data august
data august
date product utc date dissemin utc
detail relev metric lulu report pleas see cheat sheet enclos
date product utc date dissemin utc
price month
bottom line view appoint new ceo slightnetposit stock mr
lui departur add risk underli kate trend wors thought/what
reflect guidanc clearer focu cash flow plu strong balanc sheet stepped-up
expect signific rotat stock fromlonger-term investor strategi vacuum
transit on-going lack visibl deepli neg kate trend
improv new ceo could catalyst deeper valu fund start think
tpr strateg privat market financi valu potenti acquisit target price-to-earnings
today remain neutral visibl improv
announc jide zeitlin ceo announc jide zeitlin current chairman
board ceosucceed lui abruptli leav compani board
releas say remain commit multi-brand model zeitlin focu activ
drive busi perform year experi goldman sach year
experi tpr board mr zeitlin know busi well still lack experi
directlyoper brand portfoliocombin comment search futur
ceo appropri timereduc visibl kate brand stabil
long-term strategi busi howev reiter outlook
continu expect return sharehold year dividend share
repurchas cash return sharehold today stock price
valuat tp base ep
date product utc date dissemin utc
price month
clear-cut win cohort
cohort data continu show durabl updat data initi patient
cohort gc/kg show continu cornstarch reduct patient fulli discontinu
stabl benefit time hypoglycemia two patient mark benefit
week result show durabl week consist progress titrat
cornstarch keep patient metabol stabl
earli cohort data clearli differenti cohort initi updat
patient cohort gc/kg shown cornstarch reduct three patient
week though patient lowest reduct across patient dose
week reduct rel rang subject
earli data improv time hypoglycemia modest subject
cohort compani specul may attribut potenti exagger insulin
respons could murk result fast challeng couldv
exacerb steroid use intern consist result clear-cut superior
cohort point though emphas addit measur suggest clinic benefit
lower lactat level consist earli reduct liver fat fraction measur mri week
signific hyperglycemia control fast challeng base
total data enrol subject expans cohort confirm gc/kg
optim dose studi data expect trial expect begin
chang thesi result cohort could eventu lead better clinic
outcom longer follow-up expect signific nt valu creation result
data owe long timelin assum approv limit interpret stage
uncertainti potenti commerci opportun owe unclear reimbursement/
price potenti total address popul
date product utc date dissemin utc
reduc estim profit warn
retain confid chicken turnaround
lower ep estim
adjust tyson profit warn guidanc reduct
cut fy estim reflect manag guidanc
oper problem chicken busi miss higher
cost relat fire holcomb beef plant mayb spill
howev maintain target price reflect view issu
dissip complet compani benefit significantli favor global
protein industri condit protein demand foodservic volum growth prepar food
chicken busi continu under-perform peer manag cite slowdown
chicken product facil presum tray-pack follow seri product recal earlier
year curiou learn slowdown would caus miss size
lot confid new leadership team abil achiev oper turnaround
target chicken time ceo noel white group presid poultri chad martin
strong experi commod industri
valuat target price reflect price-to-earnings multipl fy ep estim
support sotp model assum stock price-to-earnings valuat improv
versu averag deflat meat price excess domest suppli export
restrict repres biggest risk target price
date product utc date dissemin utc
price month
price month
report result market close today septemb
manag feedback earn result deliv concurr analyst event
new york schedul begin et option impli price move call detail
expect upon market close expect press releas contain
financial/oper highlight well financi outlook past
fiscal year compani provid guidanc revenu non-gaap ep though
may see new metric guidanc announc analyst meet
number look street expect product revenu bill
vs cs vs cs respect expect
season averag product total revenu rel line bill
expect impli meaning deceler product subscript revenu limit
check support season strong finish despit hear difficulti achiev lofti
target concern compani evp ww sale depart post quarter-end see
preview howev expect stock react addit
transit guidanc especi impact
messag listen believ focu remain compani vision strategi
evolv cybersecur shift beyond network control applic
stand feel busi transit like necessari palo alto network
continu compet new cybersecur paradigm struggl see pan sustain
market growth rate comp multipl tailwind past yr difficulti see
transit deflationari especi vs consensu model ocf margin expans
date product utc date dissemin utc
updat fx sale
uk fx updat estim chang gbp exchang rate fx
translat impact rev mln ebitda mln ep less cent
annual achc guidanc base use achc estimate exchang
rate impact offer today fx rate hold current level remaind
year full year would impact neg rel guidanc mln revenu
mln ebitda cent ep assum estim use embed fx rate
per gbp neg impact fx would approx mln revenu mln
ebitda cent ep quarter separ manag said aug
settl rebook cross currenc swap place sinc may
receiv mln settlement paid mln revolv transact result
bp reduct interest rate appli mln debt mln reduct
uk sale commentari seen busi disrupt uk due on-go
sale process note oper priori maintain focu sinc sever sale
process alreadi addit local manag stabl help retent local
staff sale process differ uk seller level due dilig
buyer pleas interest see scenario brexit could impact
sale time think unlik impact ultim buyer interest
updat said wind close us facil cost mln
cost mln dont see signific closur ahead
two de novo still expect break-even retool uk
bed past year bed offlin end bed expect
brought back on-line labor cost uk stabil improv
sequenti recent quarter less agenc labor cost less
labor cost rev
date product utc date dissemin utc
price month
summer wound review us perform first
half year discuss sector posit head remaind
earli overal biotech investor remain cautiou macro overhang loom head
us presidenti elect concern broader economi drive investor
posit portfolio defens howev view macro issu
unlik materi fundament impact remain posit sector
follow solid execut full present detail
review saw remov key litigation-rel company-specif overhang amgen/
enbrel regeneron/pralu de-risk revenu shift investor attent futur
pipelin replenish remain key focu late-stag commerci view
favor investor purchas otezla gilead transact
galapago gener well receiv contrast share continu experi multipl
contract capit deploy continu favor share repurchas bd growth overal
cover commercial-stag compani beat consensu revenu ep expect
notabl strong perform vertex neurocrin pipelin progress continu
ahead earlier expect gilead file filgotinib steadi progress
biosimilar despit solid biotech sector continu under-perform
preview macro concern loom investor focus impact catalyst like
move needl highlight kra program updat expect
weekend world lung meet barcelona updat registr monotherapi
trial design competitor proof-of-concept data expect potenti
approv launch novarti brolucizumab pdufa octob expect compet
directli regeneron eylea expect nda file ptc/roch risdiplam
oral competitor biogen spinraza sma believ like remain backdrop
sector seller look capit premium valuat acquir larg cash
balanc easi access capit valuabl stock use transact drug price expect
remain overhang us presidenti elect
coverag larg cap biotech
date product utc date dissemin utc
bottom line report jul semi bn m/m bp season
m/m jul ex-memori bn m/m bp
season m/m recal jun/may bp season respect
apr bp peak bn ex-memori trend
season month aggreg under-grow season bp versu
cycl averag duration/depth month bp respect p-to-t declin
normal would note t-to-p growth cycl normal addit jul
ex-memori declin y/i ex-memori peak y/i base upon
season trend trough y/i -- month ppt p-to-t duration/
depth compar cycl averag ppt respect adjust
less normal t-to-p growth cycl consist averag depth/dur
analysi suggest bottom process semi two risk still loom china/u trade
uncertainti specif whether suppli chain pulled-forward demand minim
impact tariff increas overal macroeconomic concern especi light
recent invert yield curv bia construct hard cyclic bottom
certain depth/dur metric support bottom process importantli
secular thesi remain intact semi move minu plu growth sce
cyclic growth cyclic data driven economi repres growth option
see lt semi compound-annual-growth-rate improv least option would
highlight follow data
dram bit rebound still declin prior current cycl dram bit declin
y/i declin averag y/i jul dram bit
increas y/i increas y/i indic end custom deplet
inventori jul asp per bit declin y/i importantli increas m/m first time
month depth durat asp declin compar cycl averag peak-trough asp
declin durat month expect continu q/q declin
green shoot stabil emerg year-end bullish outlook
nand bit grew y/i bit y/i ytd bit y/i consist lt bit
demand growth least jul nand y/i vr june
peak month ago compar averag cycl p-to-t depth/
durat expect flattish q/q q/q memori
wfe peak p-t vr cycl averag
date product utc date dissemin utc
